Literature DB >> 11083545

Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats.

S Samnick1, S Richter, B F Romeike, A Heimann, W Feiden, O Kempski, C M Kirsch.   

Abstract

In developing iodine-123-labelled amino acid derivatives for imaging cerebral gliomas by single-photon emission tomography (SPET), we compared p-[123I]iodo-L-phenylalanine (IPA), L-[123I]iodo-1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid (ITIC) and L-3-[123I]iodo-alpha-methyltyrosine (IMT) with regard to their uptake in human glioblastoma T99 and T3868 cells, and thereafter studied the mechanisms promoting the cellular uptake. The potential of the 123I-iodinated agents for use as SPET radiopharmaceuticals was evaluated in healthy experimental rats as well as in rats with stereotactically implanted C6 gliomas. The radiopharmaceutical uptake into glioblastoma cells was rapid, temperature and pH dependent, and linear during the first 5 min. Equilibrium was reached after 15-20 min, except in the case of ITIC, the initial uptake of which gradually decreased from 15 min onwards. The radioactivity concentration in glioma cells following 30-min incubation at 37 degrees C (pH 7.4) varied from 11% to 35% of the total activity per million cells (ITIC < IMT < or = IPA). Competitive inhibition experiments using alpha-(methylamino)-isobutyric acid and 2-amino-2-norbornane-carboxylic acid, known as specific substrates for systems A and L, respectively, as well as representative amino acids preferentially transported by system ASC, indicated that IPA, like IMT, is predominantly mediated by the L and ASC transport systems, while no significant involvement of the A transport system could be demonstrated. By contrast, none of the three principal neutral amino acid transport systems (A, L and ASC) appear to be substantially involved in the uptake of ITIC into glioblastoma cells. Analysis of uptake under conditions that change the cell membrane potential, i.e. in high K+ medium, showed that the membrane potential plays an important role in ITIC uptake. Alteration of the mitochondrial activity by means of valinomycin or nigericin induces a slight increase or decrease in the radiopharmaceutical uptake, suggesting a minor contribution of the mitochondria in the uptake. IPA, IMT and ITIC passed the blood-brain barrier, and thereafter showed efflux from the brain. The radioactivity concentration in healthy rat brain 15 min following intravenous injection varied from 0.07% (ITIC) to 0.27% ID/g (IPA). In comparison, the brain uptake in the stereotactically implanted C6 glioma rats was substantially higher (up to 1.10% ID/g 15 min p.i.), with tumour-to-background ratios greater than 4. These data indicate that IPA and ITIC, like IMT, exhibit interesting biological characteristics which hold promise for in vivo brain tumour investigations by SPET.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083545     DOI: 10.1007/s002590000310

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Linda Grasfeder; Michael R Zalutsky; Bennett Chin
Journal:  Appl Radiat Isot       Date:  2011-05-19       Impact factor: 1.513

2.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

3.  123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.

Authors:  Veerle Kersemans; Bart Cornelissen; Ken Kersemans; Matthias Bauwens; Rudi A Dierckx; Bart De Spiegeleer; John Mertens; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

4.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

5.  p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma.

Authors:  Samuel Samnick; Bernd F M Romeike; Boris Kubuschok; Dirk Hellwig; Michaela Amon; Wolfgang Feiden; Michael D Menger; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

6.  Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas.

Authors:  Dirk Hellwig; Bernd F M Romeike; Ralf Ketter; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

7.  Characterization of BAT activity in rats using invasive and non-invasive techniques.

Authors:  Andreas Paulus; Petronella A van Ewijk; Emmani B M Nascimento; Marijke De Saint-Hubert; Geert Hendrikx; Andrea Vogg; Ivo Pooters; Melanie Schnijderberg; Joris Vanderlocht; Gerard Bos; Boudewijn Brans; Vera B Schrauwen-Hinderling; Felix M Mottaghy; Matthias Bauwens
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

8.  Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice.

Authors:  Tadashi Watabe; Kazuko Kaneda-Nakashima; Yoshifumi Shirakami; Yuwei Liu; Kazuhiro Ooe; Takahiro Teramoto; Atsushi Toyoshima; Eku Shimosegawa; Takashi Nakano; Yoshikatsu Kanai; Atsushi Shinohara; Jun Hatazawa
Journal:  Oncotarget       Date:  2020-04-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.